

# ANADOLU<sup>H</sup>

In Affiliation with  
JOHNS HOPKINS MEDICINE



## CURRICULUM VITAE

**NAME:** Assoc. Prof. Eda Tanrıkulu Şimşek, M.D.

**OFFICE ADDRESS:** Anadolu Medical Center

Department of Medical Oncology

Gebze, Kocaeli- TURKEY

e-mail: [eda.simsek@anadulusaglik.org](mailto:eda.simsek@anadulusaglik.org)

## SHORT BIOGRAPHY:

After graduating from Ankara University Faculty of Medicine in 2005, she completed her compulsory service in Kars in 2006. Between 2007-2012, she completed his internal medicine residency training at Istanbul University Cerrahpaşa Faculty of Medicine. In 2013, she started her medical oncology education at Marmara University Faculty of Medicine, Department of Medical Oncology, ranking 3rd in Turkey in the minor specialization exam. She completed her medical oncology specialization training in 2017 and worked as a medical oncology specialist and medical oncology unit manager at Haydarpaşa Numune Training and Research Hospital between 2018-2021. Mrs. Tanrıkulu Şimşek, who has served as an assistant and principal researcher in many international clinical studies in the field of medical

oncology, started to work as a Medical Oncology Specialist at Anadolu Medical Center as of December 2021.

**EDUCATION:**

2005 Ankara University Faculty of Medicine, Ankara

2012 Internal Medicine Specialist, İstanbul University Cerrahpaşa Faculty of Medicine

2017 Medical Oncology specialist, Marmara University Faculty of Medicine

**FOCUS OF INTEREST:**

Breast cancer

Urological cancers

Colon and rectum cancers

Malign melanoma

Personalized treatments

**PROFESSIONAL MEMBERSHIPS:**

European Society of Medical Oncology (ESMO)

American Society of Medical Oncology (ASCO)

Turkish Medical Oncology Society (TTOD)

**Awards:**

2013 Turkish Hematology Association, Hematology Thesis Award

**Courses Attended:**

- Turkish-Chinese Cooperation Project, Colorectal Cancer Exchange Program, Shanghai, China. 2014
- Oxford University Radcliffe Department of Medicine, Metastatic Colorectal Cancer Preceptorship, Oxford, England, 2015
- The CHRISTIE Preceptorship on Lung Cancer- ESMO, Manchester, England, 2016
- Roche
- European Melanoma Experience Exchange: focus on Therapy, Essen, Germany(Online), 2020

## Published Articles:

- 1- Simsek ET, Coban E, Atag E, Gungor S, Sari M, Gurleyik G. The Role of FDG PET/CT to Evaluation of Axillary Lymph Nodes after Neoadjuvant Chemotherapy in Breast Cancer. *J Coll Physicians Surg Pak*. 2021 Jul;30(7):792-797.
- 2- Tanrikulu Simsek E, Eskazan AE, Cengiz M, Ar MC, Ekizoglu S, Salihoglu A, Gulturk E, Elverdi T, Ongoren Aydin S, Senem Demiroz A, Buyru AN, Baslar Z, Ozbek U, Ferhanoglu B, Aydin Y, Tuzuner N, Soysal T. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. *J Clin Pathol*. 2016 Sep;69(9):810-6.
- 3- Tanrikulu Simsek E, Dane F. Nutrition in Cancer Patients Who Have Problems in Oral Taking. *Türkiye Klinikleri Tıbbi Onkoloji Kanser ve Beslenme Özel sayısı. Türkiye Klinikleri J Med Oncol-Special Topics*. 2016;9(3):58-64.
- 4- Tanrikulu Simsek E, Dane F. Primary Central Nervous System Lymphomas: Diagnosis, Staging and Systemic Treatment. *Erişkin Santral Sinir Sistemi Tümörleri Özel sayısı. Türkiye Klinikleri J Med Oncol-Special Topics*. 2019. p.78-83.
- 5- Tanrikulu Şimşek E, Beşiroglu M, Aktaş B, Koca S, Halil S, Alan Ö, Hasanov R, Akgül Babacan N, Öztürk MA, Kaya S, Ozdogan OC, Dane F, Yumuk PF. Can we Restart Vemurafenib after Severe Hepatotoxicity? A Case Report. *J J Gastro Hepato*. 2015, 2(4): 025.
- 6- Simsek ET, Coban E, Atag E, Gungor S, Aker F, Sari M. The Effect of FDG-PET/CT on Clinical Prognostic Staging of Breast Cancer Patients Planning Neoadjuvant Treatment. *J Coll Physicians Surg Pak*. 2021
- 7- Alan O, Akin Telli T, Ercelep O, Tanrikulu Simsek E, Basoglu Tuylu T, Mutis A, Hasanov R, Kaya S, Akgül Babacan N, Dane F, Yumuk PF. Chordoma: a case series and review of the literature. *J Med Case Rep*. 2018 Aug 27;12(1):239.
- 8- Alan O, Telli TA, Ercelep O, Hasanov R, Simsek ET, Mutis A, Ones T, Kaya H, Yumuk PF. A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy. *Curr Probl Cancer*. 2019 Aug;43(4):308-311
- 9- Kaya S, Aktas B, Tanrikulu Şimşek E, Akif Ozturk M, Dede F, Kaya H, Ugurlu U, Ozgen Z, Koca S, Halil S, Hasanov R, Alan O, Akgul Babacan N, Ercelep O, Dane F, Gumus M, Yumuk F. Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer. *J BUON*. 2017 Sep-Oct;22(5):1191-1198.
- 10- Gurleyik G, Aksu SA, Aker F, Tekyol KK, Tanrikulu E, Gurleyik E. Targeted axillary biopsy and sentinel lymph node biopsy for axillary restaging after neoadjuvant chemotherapy. *Ann Surg Treat Res*. 2021 Jun;100(6):305-312.
- 11- Kaytaz Tekyol K, Gurleyik G, Aktaş A, Aker F, Tanrikulu E, Tekyol D. Pathological Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: The Relationship Between Inflammatory Biomarkers and Molecular Subtypes. *Cureus*. 2021 Apr 30;13(4):e14774. doi: 10.7759/cureus.14774. PMID: 34094739; PMCID: PMC8164848.

- 12- Demirelli B, Babacan NA, Ercelep Ö, Öztürk MA, Kaya S, Tanrikulu E, Khalil S, Hasanov R, Alan Ö, Telli TA, Koca S, Aribal ME, Kuzan B, Dane F, Yumuk PF. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer. *Nutr Cancer*. 2021;73(2):230-238.
- 13- Demircan NC, Dane F, Ozturk MA, Babacan NA, Besiroglu M, Kaya S, Ercelep O, Tanrikulu E, Halil S, Koca S, Alan O, Hasanov R, Yumuk PF. Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy. *J BUON*. 2019 Jul-Aug;24(4):1494-1500.
- 14- Dulundu E, Attaallah W, Tilki M, Yegen C, Coskun S, Coskun M, Erdim A, Tanrikulu E, Yardimci S, Gunal O. Simultaneous resection for colorectal cancer with synchronous liver metastases is a safe procedure: Outcomes at a single center in Turkey. *Biosci Trends*. 2017 May 23;11(2):235-242.
- 15- Aydin D, Sendur MA, Kefeli U, Umut Unal O, Tastekin D, Akyol M, Tanrikulu E, Ciltas A, Bala Ustaalioglu B, Sener Dede D, Esbag O, Inal A, Bilir C, Bilici A, Harputlu H, Berk V, Sevinc A, Yildirim Ozdemir N, Yildirim E, Sonkaya A, Ali Ustaoglu M, Gumus M. Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO). *J BUON*. 2016 Sept-Oct;21(5):1242-1249.
- 16- Demirci NS, Aksoy S, Özdemir NY, Erdem GU, Ozcelik M, Tanrikulu E, Eren T, Bozkaya Y, Sahin S, Başol F, Aslan SA, Zengin N, Güllü İ. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study. *Curr Med Res Opin*. 2017 Mar;33(3):401-407.
- 17- Aydin D, Sendur MA, Kefeli U, Unal OU, Tastekin D, Akyol M, Tanrikulu E, Ciltas A, Ustaalioglu BB, Uysal M, Esbag O, Yazilitas D, Tanriverdi O, Bilici A, Arpacı E, Berk V, Yetisyigit T, Ozdemir NY, Oztop I, Alacacioglu A, Aydin O, Ozcelik M, Yildirim E, Dinc N, Gumus M. Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection. *Clin Colorectal Cancer*. 2017 Sep;16(3):220-227.
- 18- Arı MC, Büyüktaş D, Eşkazan AE, Ongören Aydın S, Tanrikulu E, Başlar Z, Buyru AN, Ferhanoglu B, Aydın Y, Tüzüner N, Soysal T. The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. *Turk J Haematol*. 2012 Sep;29(3):242-7.
- 19- Ugurlu S, Caglar E, Yesim TE, Tanrikulu E, Can G, Kadioglu P. Evaluation of thyroid nodules in Turkish population. *Intern Med*. 2008;47(4):205-9.
- 20- Ercelep O, Alan O, Telli TA, Tuylu TB, Arıkan R, Demircan NC, Simsek ET, Babacan NA, Kaya S, Dane F, Bozkurtlar E, Ones T, Lacin T, Yumuk PF. Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma. *Tumori*. 2021 Jun;107(3):231-237.
- 21- Seyahi E, Baskurt M, Melikoglu M, Akman C, Olgun DC, Simsek E, Hamuryudan V, Kucukoglu S, Yazici H. The estimated pulmonary artery pressure can be elevated in Behçet's syndrome. *Respir Med*. 2011 Nov;105(11):1739-47.

- 22- Ercelep Ö, Akın Telli T, Alan Ö, Hasanov R, Tanrikulu Şimşek E, Akgül Babacan N, Kaya S, Kaya H, Dane F, Yumuk PF. Smokers having activating egfr mutant non-small cell lung cancer might Benefit from EGFR-TKI Treatment – Single-Center Experience. Turk J Oncol 2020;35(3):334–9.
- 23- Bavunoğlu I, Balta M, Tanrikulu E, Türkmen Z, İkizceli İ. Unexpected Diagnosis in the Metropolis: Organophosphate Poisoning. JAEMCR 2012; 3(2): 52-5.
- 24- Oven B, Celik S, Okten IN, Tanrikulu E, Aliyev A, Seker M. Approachment to the Brain Metastasis without Extracranial Metastasis of the HER2 Positive Metastatic Breast Cancer. Volume 3(6): 2-6. 2020.
- 25- Alan Ö, Ercelep Ö, Akın Telli T, Tanrikulu Şimşek E, Hasanov R, Başoğlu T, Öztürk MA, Kaya S, Akgül Babacan N, Laçın T, Bozkurtlar E, Dane F, Yumuk PF. Opere Erken Evre Akciğer Kanseri Hastalarında Prognostik Faktörler Retrospektif Tek Merkez Sonuçları. Namık Kemal Tıp Dergisi 2020; 8(3): 376 - 382.